Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura

American Journal of Hematology

Volumn 87, Issue 4, 2012, Pages 430-432

  Cataland, Spero R ^a   Peyvandi, Flora ^b   Mannucci, Pier M ^b   Lämmle, Bernhard ^c   Kremer Hovinga, Johanna A ^c   Machin, Samuel J ^d   Scully, Marie ^d   Rock, Gail ^e   Gilbert, James C ^f   Yang, Shangbin ^a   Wu, Haifeng ^a   Jilma, Bernd ^g   Knoebl, Paul ^g  

^a OHIO STATE UNIVERSITY   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e UNIVERSITY OF OTTAWA   (Canada)

^f Archemix Corporation   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EGAPTIVON PEGOL; LACTATE DEHYDROGENASE; PLACEBO; THROMBIN RECEPTOR; VON WILLEBRAND FACTOR;

ADULT; AGED; BLEEDING; CATHETER INFECTION; CATHETER THROMBOSIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; LETTER; LOADING DRUG DOSE; MALE; MENTAL HEALTH; MULTICENTER STUDY; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEPSIS; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ADAM PROTEINS; ADULT; APTAMERS, NUCLEOTIDE; CATHETER-RELATED INFECTIONS; COMBINED MODALITY THERAPY; CONSCIOUSNESS DISORDERS; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; EPILEPSY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PLATELET COUNT; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VON WILLEBRAND FACTOR;

EID: 84862807272     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23106     Document Type: Letter

References (5)

1. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 2010; 50: 237-257.
2. Knobl P, Jilma B, Gilbert JC, et al. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion 2009; 49: 2181-2185.
3. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116: 2678-2686.
4. Diener JL, Daniel Lagasse HA, Duerschmied D, et al. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Hemost 2009; 7: 1155-1162.
5. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, et al. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. J Thromb Hemost 2011; 105: 545-552.